The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2; encoded by the NFE2L2) plays a key role in regulating cellular redox homeostasis and the protective antioxidant detoxification mechanisms in mammals [1]. NRF2 is a cytosolic transcription factor that regulates redox homeostasis by activating the expression of antioxidant response element (ARE)-dependent genes [2, 3]. Under normal conditions, NRF2 is downregulated by Kelch-like ECH-associated protein 1 (KEAP1), leading to its degradation [4, 5]. Under oxidative or electrophilic stress, cysteine modifications in KEAP1 stabilize NRF2, which translocates to the nucleus, dimerizes with small musculoaponeurotic fibrosarcoma (sMAF) proteins, and binds AREs to induce the transcription of cytoprotective genes [4, 6]. In this way, NRF2 drives the expression of various enzymes and signaling proteins involved in drug metabolism, antioxidant defense, and oxidative signaling, playing a crucial role in managing cellular responses to oxidative stress [7]. These enzymes include glutathione S-transferase (GST), NAD(P)H:quinone oxidoreductase 1 (NQO1), and heme oxygenase-1 (HO-1), which protect cells from oxidative damage [8].

Although NRF2 activation is beneficial in diseases characterized by oxidative stress, including neurodegenerative, cardiovascular, and metabolic disorders [8, 9], in cancer, its persistent activation can be maladaptive.

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy [2, 3] and accounts for 70–90% of cases in patients with chronic liver disease [10]. It is among the leading causes of cancer-related mortality worldwide [2, 10] and is characterized by rapid progression, late diagnosis, and poor prognosis. Major risk factors include chronic hepatitis B and C virus infections [4], alcohol abuse, aflatoxin B1 exposure, diabetes mellitus, obesity, tobacco use, iron accumulation, and nonalcoholic fatty liver disease [10]. Outcomes remain poor, with a 5-year relative survival rate of only ~18% for all stages [11], despite available treatments such as resection, liver transplantation, and systemic or locoregional therapies [12, 13], increasing to ~31% for localized disease [2]. For advanced HCC, systemic therapies are the standard of care; these include molecularly targeted agents (MTAs), chemotherapeutic drugs (CTDs), and immune checkpoint inhibitors (ICIs) [14]. Sorafenib, a multikinase inhibitor, has been widely used as first-line systemic therapy [15]; however, resistance is common, and conventional chemotherapy has shown limited efficacy, prompting the evaluation of combination regimens [16].

NRF2 signaling and lipid peroxidation are closely involved in HCC chemoresistance [10]. Oxidative stress contributes to hepatocarcinogenesis by inducing DNA damage, generating reactive oxygen and nitrogen species (ROS/RNS), and disrupting protein expression. Increased ROS can induce increased mitochondrial membrane permeability and DNA damage. According to Gao et al. [17], SLC27A5 deficiency activates the NRF2/TXNRD1 pathway due to increased lipid peroxidation in HCC. This suggests that alterations in lipid metabolism and the resulting oxidative stress/lipid peroxidation influence HCC chemoresistance, mediated in part by pathways such as NRF2 activation.

While NRF2 can act as a tumor suppressor under physiological stress, its sustained activation in HCC drives malignant progression [18]. Persistent NRF2 signaling, frequently mediated by the p62-KEAP1-NRF2 axis, promotes survival by activating ARE-dependent genes such as SLC7A11, glutathione peroxidase 4 (GPX4), NQO1, HO-1, and FTH1, which limit lipid peroxidation, regulate iron homeostasis, and protect against ferroptosis. These mechanisms confer resistance to ferroptosis-inducing agents such as erastin, sorafenib, and buthionine sulfoximine [19, 20].

Considering the interplay between oxidative stress, lipid peroxidation, and persistent NRF2 activation, targeting this pathway emerges as a promising strategy to overcome therapy resistance in HCC. The aim of this review is, therefore, to examine the dual role of NRF2 in cancer, with particular emphasis on HCC, and to analyze how its regulation of lipid peroxidation and ferroptosis influences disease progression. We also summarize current therapeutic approaches proposed to modulate this pathway and discuss their potential to complement existing HCC treatments.

ROS/RNS are continuously being generated from both endogenous metabolism and external exposures. While controlled levels of oxidants are involved in physiological processes, such as cell division, immune regulation, and stress adaptation, their excessive accumulation causes oxidative stress, damaging lipids, proteins, and nucleic acids [7, 21].

Oxidative stress activates multiple signaling pathways, including MAPKs, PI3K/AKT, and the transcription factor NRF2 [22]. Once stabilized, NRF2 translocates to the nucleus, binds to AREs, and induces cytoprotective genes such as HO-1, NQO1, SLC7A11, and GPX4, which restore redox balance and limit lipid peroxidation [23]. This regulatory axis is not merely theoretical, but it has been consistently demonstrated using natural products that activate the NRF2-ARE pathway. For example, dithiolthiones and anethole have been shown to induce phase II detoxification enzymes by activating ARE, thereby strengthening the antioxidant and detoxification capacity of cells. Kou et al. [24] describe additional dietary phytochemicals—such as curcumin, resveratrol, and quercetin—that promote ARE-dependent expression of protective enzymes, supporting the idea that diet-derived compounds may enhance cellular defenses through NRF2 signaling. By incorporating these specific examples, it becomes clear that NRF2 represents a central regulator of the adaptive response to oxidative and electrophilic stress, with translational relevance extending from basic cellular models to preventive strategies based on natural compounds [25–27].

The regulatory role of the KEAP1-NRF2 pathway has been extensively investigated in a wide range of conditions where oxidative stress plays a pivotal role, including chronic, degenerative, pulmonary, cardiovascular, and even emerging infectious diseases [8, 26–30].

These findings highlight the broad relevance of NRF2 in health and disease. In this review, however, we focus specifically on how its dysregulation contributes to HCC.

In the context of cancer, NRF2 has traditionally been considered a tumor suppressor because its cytoprotective functions are considered the main cellular defense mechanism against exogenous and endogenous insults, including xenobiotics and oxidative stress. However, several recent studies demonstrate that sustained activation of the NRF2 pathway creates an environment that favors the survival of normal and malignant cells, protecting them against oxidative stress, chemotherapeutic agents, and radiotherapy [11]. Cancer cells can exploit the protective function of this pathway to promote tumor growth and drug resistance, making NRF2 inhibitors a potential therapeutic strategy in personalized cancer treatments [12].

The NRF2 pathway can become oncogenic in cases of sustained activation, often due to somatic mutations in KEAP1 or NFE2L2, the gene encoding for NRF2, or through non-genetic mechanisms such as accumulation of p62/SQSTM1, which competes for KEAP1 binding and allows NRF2 stabilization [3]. Furthermore, NRF2 interacts with oncogenic signaling pathways. It acts synergistically with the PI3K/AKT pathway, where AKT inhibits GSK-3β, thereby preventing NRF2 phosphorylation at the DSGIS motif of its Neh6 domain, which would otherwise lead to its degradation via the E3 ligase complex β-TrCP-SKP1-CUL1-RBX1. This contributes to the persistent nuclear activity of NRF2. Furthermore, NRF2 interacts with the NOTCH1 signaling axis and promotes the expression of vascular endothelial growth factor C (VEGFC), platelet-derived growth factor C (PDGFC), and insulin-like growth factor 1 (IGF1), which promote angiogenesis and mitogenic signaling. NRF2 also antagonizes pro-inflammatory transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1 (AP-1), contributing to an immunosuppressive tumor microenvironment by reducing cytokine expression and interfering with antigen presentation [8].

These alterations are prevalent in many cancer types and are particularly relevant in HCC, where chronic liver injury from hepatitis B or C infection, alcohol abuse, or metabolic dysfunction leads to persistent oxidative stress and inflammation. NRF2 is constitutively activated by somatic mutations in the gene NFE2L2 or KEAP1, or by sequestration of KEAP1 by p62/SQSTM1. These alterations impair NRF2 degradation and result in sustained activation of its transcriptional program. In HCC, NRF2 overexpression drives a multifaceted program that includes metabolic reprogramming, immune evasion, and chemoresistance. NRF2 stimulates the pentose phosphate pathway by upregulating glucose-6-phosphate dehydrogenase (G6PD), transketolase (TKT), and 6-phosphogluconate dehydrogenase (PGD), which increases NADPH production, which is required for reductive biosynthesis and redox homeostasis. Simultaneously, NRF2 enhances serine/glycine biosynthesis by transcriptionally activating phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), and serine hydroxymethyltransferase 2 (SHMT2), through coregulation with transcription factor ATF4, which promotes proliferation and resistance to nutrient deprivation. This provides transformed hepatocytes with increased tolerance to ROS, increased metabolic flexibility, and resistance to cell death, all of which contribute to tumorigenesis, survival, and drug resistance [3, 12, 13]. The metabolic shift favors the rapid synthesis of nucleotides, lipids, and amino acids, which is necessary for tumor proliferation and maintenance of high intracellular levels of NADPH for reductive biosynthesis and ROS detoxification. Furthermore, NRF2 enhances drug resistance by inducing the expression of ATP-binding cassette (ABC) transporters such as ABC sub-family C member 1 (ABCC1) and ABC sub-family G member 2 (ABCG2), which efflux chemotherapeutic agents out of cells. It also contributes to immune evasion by repressing the antigen-presenting machinery and increasing the expression of immunosuppressive genes [14, 15].

NRF2 also interacts with oncogenic signaling pathways frequently deregulated in HCC, such as PI3K/AKT, mTOR, and NOTCH1. For example, PI3K/AKT signaling inhibits GSK-3β, which prevents phosphorylation of the Neh6 degron on NRF2, thereby blocking its degradation by the β-TrCP E3 ligase complex. This results in increased stabilization of NRF2, generating a positive feedback loop. Furthermore, NRF2 activation promotes epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) maintenance through the induction of NOTCH1, SIRT1, and aldehyde dehydrogenase (ALDH) isoforms. These functions contribute to HCC metastasis, recurrence, and resistance. Notably, NRF2’s dual role—as a protector in early liver injury and a promoter in advanced cancer—makes it a therapeutic target that requires context-specific modulation to avoid adverse effects [12, 15, 16].

Clinically, high NRF2 expression in HCC is associated with larger tumor size, vascular invasion, poor differentiation, and decreased overall survival. Therapeutic targeting of NRF2 in HCC remains challenging due to its dual nature: while inhibition can restore drug sensitivity and immunogenicity, it also risks disrupting the redox balance in normal hepatocytes. Several natural compounds and synthetic inhibitors are being investigated to modulate the KEAP1-NRF2 axis with greater specificity. Therefore, contextual modulation—guided by molecular profile of KEAP1/NFE2L2 mutations and redox signatures—emerges as a promising strategy in precision medicine for HCC [3]. Importantly, one of the most relevant consequences of sustained NRF2 activation in this context is the evasion of ferroptosis through the suppression of lipid peroxidation, which directly links NRF2 activity with therapeutic resistance.

Ferroptosis is a distinctive form of non-apoptotic cell death characterized by its dependence on intracellular iron and oxidative stress. Triggered by compounds such as erastin, it is morphologically and biochemically distinct from apoptosis, necrosis, and autophagy, and results from decreased cystine uptake and diminished antioxidant defenses [17]. Ferroptosis is mediated through iron-dependent phospholipid peroxidation, making lipid metabolism a central regulator of this form of cell death and a critical link between oxidative damage and therapeutic vulnerability in diseases such as cancer [18]. In this context, ferroptosis represents a promising alternative to overcome therapy resistance in cancer, as its induction can suppress tumor growth, improve immunotherapy responses, and offer a new strategy to attack cancer through regulated lipid peroxidation [19].

Mechanistically, NRF2 inhibits lipid peroxidation through five coordinated programs. First, it enhances cystine import and glutathione (GSH) synthesis by transactivating SLC7A11 (with the cooperation of ATF4) and GCLC/GCLM, which drives GPX4 to reduce phospholipid hydroperoxides (PLOOH→PLOH) and block ferroptosis [31]. Second, it supports the GPX4 axis—directly or GSH indirectly via GSH—to detoxify lipid peroxides at membranes [32]. Third, NRF2 maintains cytosolic NADPH by upregulating G6PD/PGD [oxidative picropodophyllin (PPP)] and ME1/IDH1 (alternative pathways), thereby supporting GSH recycling and lipid-peroxide repair systems [33]. Fourth, it shapes the labile iron pool by inducing ferritin (FTH1/FTL) and ferroportin (SLC40A1) and modulating HO-1 (HMOX1), which together tend to limit Fenton chemistry that propagates lipid peroxidation (with recognized context dependency for HO-1) [34]. Fifth, in KEAP1-deficient contexts, NRF2 can interact with the FSP1-CoQ10 system as an anti-ferroptotic pathway parallel to GPX4; the combined action of NRF2/FSP1 overcomes the resistance to ferroptosis [35].

In HCC, these NRF2 programs attenuate sorafenib-induced ferroptosis, whereas NRF2 inhibition or disruption of its downstream pathways restores lipid peroxidation and ferroptotic death (e.g., GSTZ1 sensitizes HCC to sorafenib by suppressing the NRF2/GPX4 axis) [36]. This positions NRF2 as a promising target to enhance the efficacy of ferroptosis-inducing therapies [37].

HCC remains a significant global health burden due to its aggressiveness and high recurrence rates. Traditional therapies such as resection, radiofrequency ablation, or systemic agents such as sorafenib offer limited survival benefits, often due to inherent or acquired chemoresistance. A key mechanism involved in such resistance is the sustained activation of NRF2, a key regulator of ferroptosis evasion in tumor cells [20, 21]. The function of NRF2 is twofold: while protecting normal cells from oxidative damage, sustained NRF2 activation in cancer cells promotes survival under stress by upregulating antioxidant genes (e.g., SLC7A11, HO-1, GPX4), GSH biosynthesis, and regulating iron metabolism to suppress lipid peroxidation and ferroptotic cell death, thereby facilitating tumor progression [22, 23]. For this reason, there is growing interest in targeting the NRF2 signaling axis as a therapeutic strategy in HCC, with the aim of altering its antioxidant defenses and promoting ferroptotic cell death by improving lipid peroxidation.

Various therapies have been studied to modulate the NRF2 pathway in the context of HCC. Sorafenib, a multi-kinase inhibitor widely used in the treatment of HCC, frequently presents therapeutic resistance. Studies with sorafenib-resistant HCC cell lines have shown that NRF2 signaling contributes to enhanced cell proliferation and migration, as well as cancer pluripotency, through upregulation of pluripotency markers and ABC transporter genes. Notably, NRF2 inhibition reduces these aggressive features, implying that NRF2 is a key driver of sorafenib resistance in HCC [26].

In this context, various cotreatment strategies have been developed to reduce tumor cell resistance to sorafenib, while novel compounds have also been studied. Furthermore, key intracellular targets have been identified, whose modulation has shown promising effects in improving ferroptosis and regulating NRF2 activity. These findings are summarized in Table 1 and illustrated in Figure 1.

Therapeutic strategies targeting NRF2 modulation in HCC can be classified into three categories: direct NRF2 inhibitors, upstream signaling modulators, and natural compounds with paradoxical or dual effects. These approaches converge on specific molecular nodes—including the KEAP1-NRF2 interaction, NRF2 stability and degradation, and downstream effectors such as CYP4F11—and often demonstrate synergistic potential when combined with standard therapies such as sorafenib.

Despite promising preclinical evidence, several limitations constrain the translational potential of NRF2-targeted therapies in HCC. First, the lack of clinical trials remains a major obstacle. While numerous compounds have demonstrated efficacy in vitro and in murine models, no phase I or II trials directly targeting NRF2 have been conducted in HCC patients, raising concerns about their applicability in clinical practice. Second, many current NRF2 inhibitors, such as brusatol or trigonelline, lack specificity and are associated with undesirable effects and systemic toxicity. This hampers dose optimization and increases the risk of adverse outcomes.

Tumor heterogeneity represents another limitation, as mutations or non-genetic mechanisms leading to NRF2 activation are not uniformly present across HCC subtypes. This highlights the need to stratify patients using molecular profiling before considering NRF2-targeted interventions. Furthermore, the dual role of NRF2—as a protective factor in early liver disease and a promoter of tumor survival in advanced stages—poses a therapeutic dilemma. Broad NRF2 inhibition risks exacerbating oxidative stress in non-tumorous hepatocytes, particularly in patients with cirrhosis or steatohepatitis.

Finally, there is a lack of robust biomarkers for monitoring NRF2 activity and treatment response in real time. Current studies rely on surrogate indicators, such as lipid peroxidation or GPX4 expression, which may not accurately capture NRF2 modulation. Together, these limitations underscore the need for more specific inhibitors, validated biomarkers, and carefully designed clinical studies to translate NRF2-targeted strategies into effective therapies for HCC.

These challenges, along with potential strategies to overcome them, are summarized in Figure 2, which highlights the translational barriers of NRF2-targeted therapies and outlines proposed solutions such as patient-derived models, selective inhibitors, and biomarker development.

Inhibition of the NRF2 pathway offers a promising strategy to overcome ferroptosis resistance in HCC and improve therapeutic outcomes. Preclinical studies consistently demonstrate that NRF2 inhibition enhances lipid peroxidation and synergizes with agents such as sorafenib. However, its translation into clinical practice remains complex due to tumor heterogeneity, the limited specificity of available inhibitors, and safety concerns in diseased livers. In the future, the development of selective NRF2 modulators, integration of patient stratification based on genetic and molecular profiles, and the validation of reliable biomarkers will be essential. By combining these advances with rational therapeutic regimens, NRF2-targeted approaches could open new avenues for precision medicine in drug-resistant liver cancer.